Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00820092 · ClinicalTrials.gov registry record · Phase 1
Xerecept Intravenous Dose Escalation in Japanese and Caucasian Volunteers
A Phase 1 study of Edema, sponsored by Celtic Pharma Development Services.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
- 1
- Study location
NCT00820092: Completed Phase 1 study of Edema, sponsored by Celtic Pharma Development Services.
NCT00820092 is a Phase 1 study of Edema that has completed, run by Celtic Pharma Development Services. The registered enrollment target is 38 participants, below the 462-participant average among 13 other Edema trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00820092, a Phase 1 study of Edema, has completed, sponsored by Celtic Pharma Development Services.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
- 1
- Study location
Study Summary
1. To investigate the safety and tolerability of Xerecept during and following a 24-hour intravenous administration to healthy Japanese to healthy Japanese and Caucasian subjects 2. To compare the PK profile of hCRF during and following a 24-hour intravenous Xerecept administration between healthy Japanese and Caucasian subjects
Conditions Studied
Interventions
- DRUG Xerecept 1.0
- DRUG Xerecept 2.0
- DRUG Xerecept 3.0
Study Locations (1)
California
- West Coast Clinical Trials - Cypress
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2008-12 |
| Est. Completion | 2009-04 |
| Phase | Phase 1 |
What the finished NCT00820092 record still lists
NCT00820092 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 462-participant average among 13 other Edema trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Edema appearing as the primary indexed condition, and to 3 interventions - of which Xerecept 1.0 is the first listed.
NCT00820092 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00820092 about?
NCT00820092 is a clinical study titled "Xerecept Intravenous Dose Escalation in Japanese and Caucasian Volunteers". 1. To investigate the safety and tolerability of Xerecept during and following a 24-hour intravenous administration to healthy Japanese to healthy Japanese and Caucasian subjects 2. To compare the PK profile of hCRF during and following a 24-hour intravenous Xerecept administration between healthy J...
What is the current status of trial NCT00820092?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2008-12. Estimated completion is 2009-04.
What conditions does trial NCT00820092 study?
This clinical trial studies the following conditions: Edema.
What interventions are being tested in trial NCT00820092?
The interventions under investigation include: Xerecept 1.0 (DRUG), Xerecept 2.0 (DRUG), Xerecept 3.0 (DRUG).
Who is sponsoring clinical trial NCT00820092?
This trial is sponsored by Celtic Pharma Development Services, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00820092 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Edema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00820092's enrollment target sits among peer trials
38 10th of 13 higher than 4 of 13 other Edema trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Edema trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Surgical Evaluation for Upper Extremity Lymphedema (BioBridge)
RECRUITING · NA
-
Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome.
RECRUITING
-
LymphBridge: Surgical Evaluation for Breast Cancer-Associated Lymphedema (BioBridge)
RECRUITING · NA
-
Diuretic Tuner Clinical Decision Support
RECRUITING · NA
-
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
RECRUITING
-
Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia